4//SEC Filing
Cislini Jeff 4
Accession 0001610717-25-000383
CIK 0001628171other
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 4:23 PM ET
Size
8.6 KB
Accession
0001610717-25-000383
Insider Transaction Report
Form 4
Cislini Jeff
General Counsel
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-11-18−13,388→ 0 totalExercise: $42.45From: 2025-03-04Exp: 2031-03-03→ Common Stock (13,388 underlying) - Sale
Common Stock
2025-11-18$70.14/sh−13,388$939,008→ 50,425 total - Exercise/Conversion
Common Stock
2025-11-18$42.45/sh+13,388$568,321→ 63,813 total
Footnotes (3)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.
- [F2]Includes 43,910 restricted stock units.
- [F3]This transaction was executed in multiple trades in prices ranging from $70.00 to $70.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Documents
Issuer
Revolution Medicines, Inc.
CIK 0001628171
Entity typeother
Related Parties
1- filerCIK 0001969082
Filing Metadata
- Form type
- 4
- Filed
- Nov 19, 7:00 PM ET
- Accepted
- Nov 20, 4:23 PM ET
- Size
- 8.6 KB